Back to top
more

AVEO Pharmaceuticals, Inc. (AVEO)

(Delayed Data from NSDQ)

$0.94 USD

0.94
1,186,754

+0.04 (4.01%)

Updated May 3, 2019 04:00 PM ET

After-Market: $0.91 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Better trading starts here.

Zacks News

Has Arcutis Biotherapeutics (ARQT) Outpaced Other Medical Stocks This Year?

Here is how Arcutis Biotherapeutics, Inc. (ARQT) and AVEO Pharmaceuticals (AVEO) have performed compared to their sector so far this year.

Wall Street Analysts Predict a 100% Upside in AVEO (AVEO): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 99.9% in AVEO (AVEO). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

What Makes AVEO (AVEO) a Good Fit for "Trend Investing"

AVEO (AVEO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Has AVEO Pharmaceuticals (AVEO) Outpaced Other Medical Stocks This Year?

Here is how AVEO Pharmaceuticals (AVEO) and Butterfly Network, Inc. (BFLY) have performed compared to their sector so far this year.

Wall Street Analysts Believe AVEO (AVEO) Could Rally 113%: Here's is How to Trade

The consensus price target hints at an 113.2% upside potential for AVEO (AVEO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Recent Price Trend in AVEO (AVEO) is Your Friend, Here's Why

AVEO (AVEO) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Misses Revenue Estimates

AVEO (AVEO) delivered earnings and revenue surprises of 11.11% and 2.66%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Precigen, Inc. (PGEN) to Report a Decline in Earnings: What to Look Out for

Precigen, Inc. (PGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AVEO Pharmaceuticals (AVEO) Reports Q1 Loss, Misses Revenue Estimates

AVEO (AVEO) delivered earnings and revenue surprises of -15.38% and 1.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

AVEO Pharmaceuticals (AVEO) Reports Q4 Loss, Misses Revenue Estimates

AVEO (AVEO) delivered earnings and revenue surprises of 40% and 6.87%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Lineage Cell (LCTX) Reports Q4 Loss

Lineage Cell (LCTX) delivered earnings and revenue surprises of -25% and 0%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Calyxt (CLXT) Reports Q4 Loss, Misses Revenue Estimates

Calyxt (CLXT) delivered earnings and revenue surprises of 17.39% and 42.28%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

AVEO Pharmaceuticals (AVEO) Reports Q3 Loss, Tops Revenue Estimates

AVEO (AVEO) delivered earnings and revenue surprises of 16.67% and 6.21%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate AVEO Pharmaceuticals (AVEO) to Report a Decline in Earnings: What to Look Out for

AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AVEO Pharmaceuticals (AVEO) Reports Q2 Loss, Misses Revenue Estimates

AVEO (AVEO) delivered earnings and revenue surprises of -2.13% and -2.58%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

AVEO Pharmaceuticals (AVEO) Reports Q1 Loss, Tops Revenue Estimates

AVEO (AVEO) delivered earnings and revenue surprises of -30.91% and 42.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: AVEO Pharmaceuticals (AVEO) Q1 Earnings Expected to Decline

AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can AVEO (AVEO) Run Higher on Strong Earnings Estimate Revisions?

AVEO (AVEO) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.

AVEO Pharmaceuticals (AVEO) Reports Q4 Loss, Lags Revenue Estimates

AVEO (AVEO) delivered earnings and revenue surprises of -15.79% and -70.79%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

AVEO Collaborates with Bristol Myers to Conduct Combo Study

AVEO forges an alliance with Bristol Myers to evaluate Fotivda in combination with Opdivo for RCC.

AVEO (AVEO) Stock Jumps 89.1%: Will It Continue to Soar?

AVEO (AVEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Earnings Preview: AVEO Pharmaceuticals (AVEO) Q4 Earnings Expected to Decline

AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AVEO Pharmaceuticals (AVEO) Reports Q3 Loss, Lags Revenue Estimates

AVEO (AVEO) delivered earnings and revenue surprises of -37.50% and -5.39%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate AVEO Pharmaceuticals (AVEO) to Report a Decline in Earnings: What to Look Out for

AVEO (AVEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

What Awaits AVEO Pharmaceuticals (AVEO) in Q3 Earnings?

On AVEO Pharmaceuticals' (AVEO) third-quarter earnings call, investor focus will be on the updates related to its NDA that seeks an approval for tivozanib to treat RCC in the United States.